Cipla did not share a great deal of detail on the much publicized licensing pact with Gilead Sciences for remdesivir at the firm’s fourth-quarter 2020 earnings call but the management drew attention to the momentum in the respiratory segment, where the firm has now filed an ANDA for a generic version of GlaxoSmithKline’s Advair Diskus (salmeterol/fluticasone) in the US.
Cipla Propels 'Lung Leadership' Plans
Reimagines Operating Models As Q4 Sales Hit By COVID-19
Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.
